Summary
PROJECT SUMMARY Metabolic diseases, such as obesity and type 2 diabetes (T2D), are characterized by perturbations of glucose tolerance, pancreatic beta cell function, energy imbalance, appetite regulation, and other unknown pathways. Clinical and genetic studies in humans and animal experiments have also implicated gut microbiota and products derived from their metabolism of dietary nutrients as important mediators of metabolic risk. In this regard, we have observed protective associations between plasma levels of indole-3-propionic acid (IPA) – a metabolite generated entirely by gut bacteria
